Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Poznansky

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Cancer Research|July 12, 2011
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancerElda Righi, Satoshi Kashiwagi, Jianping Yuan, et al.
Plos One|April 13, 2011
R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodesMichael Santosuosso, Elda Righi, E David Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional ChondrosarcomaBinghao Li, Guoqi Li, Xiaobo Yan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cell Reports. Medicine|December 10, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cancer Immunology Research|March 8, 2018
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral ImmunosuppressionBinghao Li, Yang Zeng, Patrick M Reeves, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Plos One|July 27, 2010
R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate modelsNagadenahalli B Siddappa, Jennifer D Watkins, Klemens J Wassermann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2025
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 AlterationsIbiayi Dagogo-Jack, Owen Mitchell, Elizabeth Codd, et al.
Frontiers in Immunology|March 5, 2019
Promiscuous <i>Coxiella burnetii</i> CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever VaccineAnja Scholzen, Guilhem Richard, Leonard Moise, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Cancer Research|July 12, 2011
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancerElda Righi, Satoshi Kashiwagi, Jianping Yuan, et al.
Plos One|April 13, 2011
R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodesMichael Santosuosso, Elda Righi, E David Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional ChondrosarcomaBinghao Li, Guoqi Li, Xiaobo Yan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cell Reports. Medicine|December 10, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cancer Immunology Research|March 8, 2018
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral ImmunosuppressionBinghao Li, Yang Zeng, Patrick M Reeves, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Plos One|July 27, 2010
R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate modelsNagadenahalli B Siddappa, Jennifer D Watkins, Klemens J Wassermann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2025
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 AlterationsIbiayi Dagogo-Jack, Owen Mitchell, Elizabeth Codd, et al.
Frontiers in Immunology|March 5, 2019
Promiscuous <i>Coxiella burnetii</i> CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever VaccineAnja Scholzen, Guilhem Richard, Leonard Moise, et al.
Pageof 11